Fig. 4
From: A triple hormone receptor ER, AR, and VDR signature is a robust prognosis predictor in breast cancer
THR-70 is prognostic in the SurvExpress Meta-10 cohort, comprising samples from 10 different datasets. THR-70 shows a significant association with recurrence-free survival (RFS, HR = 2.5 CI: 2.0—3.1, p = 3.7e-16) (A) and distant metastasis-free survival (DMFS, HR = 3.7 CI: 2.7—5.6, p = 6.7e-15) (B). It is prognostic in both lymph node positive (LN + , HR = 9.7 CI: 5.0—18.7, p = 9.6e-12) (C) and negative (LN-, HR = 3.3 CI: 2.4—4.5, p = 2.7e-15) (D) disease, as well as in patients treated with endocrine therapy post surgery (ETPS, HR = 4.3 CI: 3.0—6.3, p = 1.4e-14) (E), and those who did not receive neoadjuvant treatment (NTPS, HR = 2.3 CI: 1.8—2.8, p = 8.7e-17) (F). 95% confidence interval (CI); hazard ratio (HR)